We report a patient with Ph chromosome-positive CML who underwent an HLA-identical T cell-depleted BMT from a sibling donor. DNA polymorphism analysis showed complete donor chimaerism after BMT, followed by mixed chimaerism of granulocytes, natural killer cells and B lymphocytes, with T lymphocytes hostderived at day +120 post BMT. From month +20 haematopoiesis was exclusively of host origin in all cell lineages. RT-PCR was used in order to detect residual disease, but at the time, analysis did not show BCR-ABL transcripts. This case is unusual in that non-malignant stem cells of recipient origin survived the transplant and reconstituted haematopoiesis after BMT. Two years post transplant, no molecular or haematological relapse was documented. The observation that subsequent recipient recovery without molecular relapse implies that, at least in this case, the GVL effect can occur in the absence of donor T cells. Keywords: CML; BMT; mixed chimaerism; autologous reconstitution; BCR-ABL negative Allogeneic bone marrow transplantation (BMT) is presently the most effective curative treatment for chronic myelogenous leukaemia (CML).
Allogeneic bone marrow transplantation (BMT) is presently the most effective curative treatment for chronic myelogenous leukaemia (CML). 1 Despite a successful outcome in many patients, relapse occurs in approximately 10% of those receiving unmanipulated grafts. 2 Leukaemia relapse presumably results from the inability of the conditioning regimen to eliminate all recipient leukaemic cells. Ideally, following BMT, the recipient's bone marrow should be completely ablated by the conditioning regimen, facilitating the engraftment of donor haematopoietic stem cell and giving rise to a complete donor haematopoietic chimaera.
After unmanipulated transplants for CML, mixed chimaerism (MC) seems to predict cytogenetic and haematological relapse in BCR-ABL-positive long-term survivors, while persistent donor chimaerism is consistent with disease-free survival. 3, 4 We report here a highly unusual patient with Ph chromoCorrespondence: Dr J Serrano, Haematology Department, University Hospital Reina Sofía, Avda. Menéndez Pidal S/N, 14004-Córdoba, Spain Received 16 February 1998; accepted 29 April 1998 some-positive CML who recovered autologous haematopoiesis in all cell lineages, while maintaining a complete molecular remission 2 years after T cell-depleted allogeneic BMT.
Case report
A 46-year-old man was diagnosed with Ph-positive CML in February 1995. He presented with a WBC of 56 × 10 9 /l and splenomegaly. He was treated initially with hydroxyurea and subsequently interferon-␣ was administered, with good haematological control and a cytogenetic response of 15% Ph negativity.
In February 1996, he underwent allogeneic BMT from an HLA-identical sibling donor. As the conditioning regimen he received cyclophosphamide (60 mg/kg body weight × 2) and total body irradiation (8 × 165 cGy). A nucleated cell dose of 0.54 × 10 8 /kg was infused. GVHD prophylaxis consisted of CsA (6 mg/kg/day) with total CD4 + T cell depletion and partial CD8 + T cell depletion. 5 T cell depletion was carried out by sequential incubation of the marrow with anti-CD4 and anti-CD8 moAb-coated magnetic microspheres; 1 × 10 6 /kg CD8 + T cells were preserved before the CD8 + T cell depletion and added-back to the CD4 + CD8 + -depleted marrow. All blood products were filtered and irradiated before infusion. Neutrophil recovery occurred at day +21 post BMT. The initial post-transplant period was relatively uncomplicated without evidence of acute GVHD. On day +32 post BMT, he was discharged, although he remained red cell dependent for 3 months. After 25 months post-BMT follow-up, the patient remained clinically well with molecular and haematologic complete remission.
Materials, methods and results
Chimaerism analysis was performed on DNA extracted from peripheral blood monthly post BMT. DNA polymorphism analysis that distinguished between host and donor cells was studied using the PCR method as previously described. 6 Immediately after BMT, haematopoiesis was unambiguously of donor origin, but mixed chimaerism was found at day +120, and PCR analysis of minisatellites in highly purified cell subpopulations was evaluated. Cell separations were performed using immunomagnetic bead (Dynal, Oslo, Norway) either coupled with the specific antibody (CD3, CD19, CD15) or coupled in a first-step reaction with monoclonal antibody (CD56 (Becton Dickinson, San Jose, CA, USA)) and after washing with antimouse IgG. These analyses documented host-derived T lymphocytes, but granulocytes, B lymphocytes and natural killer cells showed mixed chimaerism at day +120 ( Figure 1 ) and from month +20 haematopoiesis was exclusively of host origin in all cell lineages. No evidence of minimal residual disease (MRD), as identified using the BCR-ABL mRNA RT-PCR assay, was detected at day +120 or in subsequent analyses ( Figure 2) .
Discussion
There are a few reports in the literature of transient recovery of host-derived Ph-negative haemopoiesis post BMT for CML as assessed by cytogenetic or molecular analyses. However, a durable molecular remission in such patients has not been reported. [7] [8] [9] Recently, Wakui et al 8 reported a post-BMT CML case who regained complete host-derived haematopoiesis with long molecular remission, but mixed T cell chimaerism in the peripheral blood was noted. Our case is unique as non-malignant cells of host origin were able to re-establish haemopoiesis 4 months after transplant and predominate for more than 2 years without molecular or haematological relapse.
After BMT, in many cases of CML, the mechanism of cure does not derive solely from marrow ablative treatment but also from an additional progressive antileukaemic effect of donor immunocompetent cells termed the graft-versus- leukaemia (GVL) effect. The importance of the GVL effect in CML is supported by the fact that recipients of T celldepleted marrow or syngeneic BMT have a high incidence of post-transplant relapse. 10 It is also documented that mixed chimaerism, particularly T cell chimaerism, is associated with BCR-ABL detection and a higher risk of relapse after BMT for CML. 11 Additional evidence that supports the role of T cells in mediating GVL effect comes from studies using donor leucocyte infusions to induce remissions in patients with CML who relapse post BMT. 12 It is plausible that if MC developed post BMT, donor T cells could become tolerant to host myeloid cells, including residual leukaemic cells, resulting in abrogation of any GVL effect. However, in our patient, highly purified cell population analysis disclosed that T lymphocytes were host-derived and were persistently BCR-ABL negative. Thus, MC on manipulated BMT for CML is not a predictor of impending relapse, and more important, is not always associated with minimal residual disease (MRD). Lack of MRD in our patient could be independent of the GVL effect, because T cells are of host origin, and he did not develop GVHD, and thus did not benefit from their immunologic advantage. In this case, non-malignant host myeloid progenitor cells survived the conditioning regimen and would have had a growth advantage over neoplastic cells. This clinical observation confirmed the findings of Coulombel et al, 13 who demonstrated, using long-term culture techniques, that normal haematopoietic precursors are present during the chronic phase of the disease and have a proliferative advantage over leukaemic Ph-positive progenitor cells, which could also support the potential use of autologous BMT for CML in the early phase of disease.
It may also be speculated that a subset of memory T 4 host cells could have eradicated the Ph clone when there was a low leukaemic cell burden after the conditioning regimen. This suggests that the GVL effect does not always require the presence of donor haemopoiesis. Alternatively, it is possible that the small number of infused donor T cells could have survived for a short time and suppressed the Ph chromosome-positive clone to a lesser extent than the residual normal haematopoiesis.
Although the mechanism of the GVL effect and its association with T cells and relapse remains unclear, attempts at elucidation should be made to allow prediction and therapeutic application of these immune reactions.
